Altimmune Inc (ALT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Altimmune Inc (ALT) has a cash flow conversion efficiency ratio of -0.086x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.45 Million) by net assets ($224.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Altimmune Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Altimmune Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Altimmune Inc debt and liabilities for a breakdown of total debt and financial obligations.
Altimmune Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Altimmune Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ferm. Casino Mun. Canne
PA:FCMC
|
0.020x |
|
Aclaris Therapeutics Inc
NASDAQ:ACRS
|
-0.091x |
|
Alcor Micro
TWO:8054
|
-0.035x |
|
Beijing Hanjian Heshan Pipeline Co Ltd
SHG:603616
|
-0.093x |
|
NUIX Ltd
AU:NXL
|
0.069x |
|
NEL ASA ADR/30 NK -20
F:D7GA
|
-0.003x |
|
Digi Communications NV
RO:DIGI
|
0.085x |
|
J&V Energy Tech Co Ltd
TW:6869
|
0.024x |
Annual Cash Flow Conversion Efficiency for Altimmune Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Altimmune Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Altimmune Inc (ALT) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $224.89 Million | $-67.53 Million | -0.300x | +53.55% |
| 2024-12-31 | $123.51 Million | $-79.85 Million | -0.647x | -65.53% |
| 2023-12-31 | $194.10 Million | $-75.81 Million | -0.391x | -15.63% |
| 2022-12-31 | $185.29 Million | $-62.59 Million | -0.338x | +14.03% |
| 2021-12-31 | $199.13 Million | $-78.24 Million | -0.393x | -157.70% |
| 2020-12-31 | $225.88 Million | $-34.44 Million | -0.152x | +27.72% |
| 2019-12-31 | $45.52 Million | $-9.60 Million | -0.211x | -8.54% |
| 2018-12-31 | $48.31 Million | $-9.39 Million | -0.194x | +53.20% |
| 2017-12-31 | $48.68 Million | $-20.21 Million | -0.415x | -104.01% |
| 2016-12-31 | $19.46 Million | $201.51 Million | 10.355x | +5461.03% |
| 2015-12-31 | $16.65 Million | $-3.22 Million | -0.193x | +58.34% |
| 2014-12-31 | $18.27 Million | $-8.47 Million | -0.464x | +52.54% |
| 2013-12-31 | $7.34 Million | $-7.17 Million | -0.977x | -391.08% |
| 2012-12-31 | $11.67 Million | $-2.32 Million | -0.199x | +59.61% |
| 2011-12-31 | $15.85 Million | $-7.81 Million | -0.493x | +59.53% |
| 2010-12-31 | $12.21 Million | $-14.86 Million | -1.217x | +91.85% |
| 2009-12-31 | $1.88 Million | $-28.15 Million | -14.936x | -2046.03% |
| 2008-12-31 | $18.96 Million | $-13.20 Million | -0.696x | -107.07% |
| 2007-12-31 | $40.57 Million | $-13.64 Million | -0.336x | -1355.97% |
| 2006-12-31 | $57.11 Million | $1.53 Million | 0.027x | +236.37% |
| 2005-12-31 | $69.68 Million | $554.33K | 0.008x | -- |
About Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.